Clinical Trials

We conduct clinical trials to evaluate the safety, efficacy and risk / benefit profile of investigational medical products in development. We conduct clinical trials in various regulatory jurisdictions (US, UK, EU, and other countries) based on our clinical development plans.

View our ongoing hemophilia b trials and other clinical research for our Hemophilia Program:

View our clinical trials for our LockBody Program:

For additional detail, please visit www.clinicaltrials.gov (US), www.clinicaltrialsregister.eu (EU), or registries in other jurisdictions.

View our Expanded Access Policy for investigational medical products.

Note: These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration or the European Medicines Agency or other regulators.

This information is only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

Scroll to Top
pipeline chart header registrational white
SerpinPC

Overview
SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678, NCT05789524, NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Disease

Hemophilia B